TCMD · XBRL financial data

Tactile Systems Technology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TCMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	187,130	208,057	246,785	274,423	292,984	329,522
Cost of revenue	54,320	59,844	70,809	79,290	76,296	79,376
Gross profit	132,810	148,213	175,976	195,133	216,688	250,146
Research and development	5,264	5,659	7,088	7,823	8,832	8,481
General and administrative	51,540	56,802	60,796	62,074	71,135	88,705
Total operating expenses	136,438	149,975	188,734	177,092	194,507	220,867
Operating income (loss)	(3,628)	(1,762)	(12,758)	18,041	22,181	29,279
Interest income	—	—	60	1,874	3,384	3,097
Interest expense	—	—	2,788	4,147	2,085	1,038
Income tax expense (benefit)	(1,641)	9,518	2,393	(12,745)	6,529	12,253
Net income (loss)	(620)	(11,811)	(17,866)	28,515	16,960	19,086
Earnings per share, basic USD per share	(0.03)	(0.60)	(0.89)	1.24	0.71	0.83
Earnings per share, diluted USD per share	(0.03)	(0.60)	(0.89)	1.23	0.70	0.82
Weighted average shares, basic thousands of shares	19,347	19,719	20,068	22,925	23,884	22,873
Weighted average shares, diluted thousands of shares	19,347	19,719	20,068	23,176	24,138	23,295

Fiscal years (TCMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	47,855	28,229	21,929	61,033	94,367	83,446
Marketable securities	0	—	—	—	—	—
Accounts receivable	43,849	49,478	54,826	43,173	44,937	43,876
Inventory	18,563	19,217	23,124	22,527	18,666	14,025
Prepaid and other current assets	2,638	4,141	3,754	4,366	5,053	8,066
Total current assets	123,613	113,547	119,763	145,294	177,563	165,167
Property and equipment, net	6,957	6,750	6,077	6,195	5,603	5,117
Right-of-use asset	20,132	23,984	21,322	19,128	16,633	13,798
Goodwill	—	31,063	31,063	31,063	31,063	31,063
Total assets	174,087	244,270	254,996	281,438	297,924	273,942
Accounts payable	4,197	5,023	9,984	6,659	5,648	4,968
Accrued liabilities	4,423	5,262	9,240	5,904	7,780	8,531
Total current liabilities	26,714	34,461	64,330	41,057	40,704	40,957
Lease liability, non-current	19,388	23,354	20,866	18,436	15,955	12,763
Total liabilities	49,337	116,043	133,596	87,796	81,327	55,040
Retained earnings (accumulated deficit)	20,056	8,245	(9,621)	18,894	35,854	54,940
Total stockholders' equity	124,750	128,227	121,400	193,642	216,597	218,902
Total liabilities and equity	174,087	244,270	254,996	281,438	297,924	273,942
Common shares outstanding (cover page) thousands of shares	19,508	19,885	20,251	23,601	23,585	22,439

Fiscal years (TCMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(620)	(11,811)	(17,866)	28,515	16,960	19,086
Stock-based compensation	10,689	10,173	9,600	7,547	7,819	8,357
Depreciation and amortization	2,794	3,681	6,268	6,539	6,792	6,643
Net cash from operating activities	2,794	2,631	5,209	35,855	40,655	42,811
Purchases of property and equipment	2,059	2,103	1,780	2,324	2,392	2,380
Net cash from investing activities	20,179	(82,184)	(1,909)	(2,481)	(2,497)	(2,535)
Proceeds from issuing common stock	2,898	2,312	1,286	34,625	—	—
Share repurchases	—	—	—	—	3,508	26,561
Net cash from financing activities	2,112	59,927	(9,600)	5,730	(4,824)	(51,197)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Tactile Systems Technology	75,110	91,858	11,978*	22.4M	—	Q3 FY26 10-QSep 30, 2026
Electromed	20,450	19,417*	2,994*	8.4M	—	Q4 FY26 10-KJun 30, 2026
Orasure Technologies	160,582	30,639	(9,921)*	69.0M	16.2 quarters	Q2 FY26 10-QJun 30, 2026
Cerus	16,350	57,714	3,007*	202.0M	—	Q3 FY26 10-QSep 30, 2026
SANUWAVE Health	9,376	9,739	425*	8.6M	—	Q2 FY26 10-QJun 30, 2026
Inogen	87,276	95,084	2,946*	26.5M	—	Q2 FY26 10-QJun 30, 2026
Bioventus	30,709	142,442	20,658*	not reported	—	Q3 FY26 10-QSep 26, 2026
Treace Medical Concepts	12,610	45,376	(4,698)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	13,647	not reported	(4,235)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 3:27 PM ET. The filing on SEC.gov is the record.